Therapeutic Areas

Our R&D efforts are focused on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.


We endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies.
Please visit here for more information


For more than 25 years, Takeda has focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs in gastroenterology (GI). Takeda is leading in areas of GI associated with high unmet need, such as inflammatory bowel disease, GI acid-related diseases and GI motility disorders.

Discourse and progress in intestinal
failure care

Rare Diseases

Takeda is fully committed to fight against rare diseases, maximizing value from approved brands and advancing treatments in the pipeline across phase 1 to 3. The Rare Diseases Therapeutic Area Unit will focus initially on Shire’s areas of expertise in hematology, immunology and lysosomal storage disorders (LSDs). 
Please visit here for more information


Neuropsychiatric disorders are complex multifaceted conditions that affect the spectrum of mental health. We aspire to provide innovative medicines for targeted patient populations suffering from neuropsychiatric disorders for whom there are no treatments available. 

Plasma-Derived Therapies

Takeda is committed to further enhancing its leadership in Plasma-Derived Therapies. We offer a best-in-class portfolio of therapies with proven efficacy and established safety across hemophilia, inhibitors, as well as von Willebrand disease.
Please visit here for more information


Vaccines have transformed global public health. Our world-class vaccine team is addressing unmet medical needs through vaccine development against infectious diseases, while using innovative development platforms and collaborating with leading partners. 
Please visit here for more information

Related Content